The anti-tumor effect of EpCAM-targeting treatment with Ec1-LoPE alone or in combination with the HER2-targeting mAb trastuzumab was evaluated in BALB/c nu/nu mice bearing EpCAM- and HER2-expressing SKOV3 xenografts. This evidence concerns the gene ERBB2 and neoplasm.